301 related articles for article (PubMed ID: 29069866)
1. Germline mutations in pancreatic cancer and potential new therapeutic options.
Pihlak R; Valle JW; McNamara MG
Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
[TBL] [Abstract][Full Text] [Related]
2. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population.
Hata T; Mizuma M; Motoi F; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Furukawa T; Unno M
Ann Gastroenterol Surg; 2021 Nov; 5(6):853-864. PubMed ID: 34755017
[TBL] [Abstract][Full Text] [Related]
3. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract][Full Text] [Related]
5. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
Pantaleo A; Forte G; Fasano C; Lepore Signorile M; Sanese P; De Marco K; Di Nicola E; Latrofa M; Grossi V; Disciglio V; Simone C
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201484
[TBL] [Abstract][Full Text] [Related]
7. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
[TBL] [Abstract][Full Text] [Related]
8. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
[TBL] [Abstract][Full Text] [Related]
9. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
10. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
11. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
[TBL] [Abstract][Full Text] [Related]
13. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
14. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
16. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
Casolino R; Corbo V; Beer P; Hwang CI; Paiella S; Silvestri V; Ottini L; Biankin AV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805011
[TBL] [Abstract][Full Text] [Related]
17. The role of PARP inhibitors in
Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies in BRCA-positive pancreatic cancer.
Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
[TBL] [Abstract][Full Text] [Related]
19.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
20. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
Kasuga A; Okamoto T; Udagawa S; Mori C; Mie T; Furukawa T; Yamada Y; Takeda T; Matsuyama M; Sasaki T; Ozaka M; Ueki A; Sasahira N
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
